

Resource Summary Report

Generated by [kravitz2](#) on Sep 4, 2026

Shire

RRID:SCR_003984

Type: Tool

Proper Citation

Shire (RRID:SCR_003984)

Resource Information

URL: <http://www.shire.com/>

Proper Citation: Shire (RRID:SCR_003984)

Description: Global specialty biopharmaceutical company that focuses on developing treatments for conditions where the impact of their medicines can make an immediate and tangible difference for patients. They provide treatments in Neuroscience, Rare Diseases, Gastrointestinal, and Internal Medicine. This might be a therapy to treat an extremely rare and life-threatening disease like Hunter syndrome or Fabry disease; or a medicine for a specialist condition like ADHD or ulcerative colitis which if not treated effectively, can dramatically affect the lives of the patient and their whole family. Shire was acquired by Takeda Pharmaceutical company on January 8, 2019.

Abbreviations: Shire

Synonyms: Takeda Pharmaceutical, Shire plc, Fibrotech Therapeutics

Resource Type: commercial organization

Keywords: pharmaceutical, fibrotech therapeutics pty ltd., fibrotech therapeutics pty ltd, fibrotech therapeutics, fibrotech, medicine, drug

Resource Name: Shire

Resource ID: SCR_003984

Alternate IDs: nlx_158391

Record Creation Time: 20220129T080222+0000

Record Last Update: 20260903T234650+0000

Ratings and Alerts

No rating or validation information has been found for Shire.

No alerts have been found for Shire.

Data and Source Information

Source: [SciCrunch Registry](#)

Usage and Citation Metrics

We found 15 mentions in open access literature.

Listed below are recent publications. The full list is available at [kravitz2](#) .

Gebremichael D, et al. (2024) Investigation of Microbial Quality of Milk and Milk Products and Isolations of Some Major Bacteria in the Central and Northwestern Zones of Tigray, Ethiopia. *Veterinary medicine international*, 2024, 9989527.

Clement S, et al. (2024) To burn or not to burn: governance of wildfires in Australia. *Ecology and society : a journal of integrative science for resilience and sustainability*, 29(1), 1.

Bhave AG, et al. (2022) Stress-testing development pathways under a changing climate: water-energy-food security in the lake Malawi-Shire river system. *Philosophical transactions. Series A, Mathematical, physical, and engineering sciences*, 380(2221), 20210134.

Sun Y, et al. (2020) Systemic enzyme delivery by blood-brain barrier-penetrating SapC-DOPS nanovesicles for treatment of neuronopathic Gaucher disease. *EBioMedicine*, 55, 102735.

Carballido JM, et al. (2020) The Emerging Jamboree of Transformative Therapies for Autoimmune Diseases. *Frontiers in immunology*, 11, 472.

Chen Y, et al. (2018) Overcoming Limitations Inherent in Sulfamidase to Improve Mucopolysaccharidosis IIIA Gene Therapy. *Molecular therapy : the journal of the American Society of Gene Therapy*, 26(4), 1118.

Welford RWD, et al. (2018) Glucosylceramide synthase inhibition with lucerastat lowers globotriaosylceramide and lysosome staining in cultured fibroblasts from Fabry patients with different mutation types. *Human molecular genetics*, 27(19), 3392.

Li X, et al. (2017) Ningnanmycin inhibits tobacco mosaic virus virulence by binding directly to its coat protein discs. *Oncotarget*, 8(47), 82446.

Kalkum G, et al. (2016) Paediatric Fabry disease: prognostic significance of ocular changes for disease severity. *BMC ophthalmology*, 16(1), 202.

Li X, et al. (2016) New Strategies and Methods to Study Interactions between Tobacco Mosaic Virus Coat Protein and Its Inhibitors. *International journal of molecular sciences*,

17(3), 252.

Arnold LE, et al. (2015) Effect of treatment modality on long-term outcomes in attention-deficit/hyperactivity disorder: a systematic review. PloS one, 10(2), e0116407.

Kilarski LL, et al. (2015) Prevalence of CADASIL and Fabry Disease in a Cohort of MRI Defined Younger Onset Lacunar Stroke. PloS one, 10(8), e0136352.

Storebø OJ, et al. (2015) Methylphenidate for attention-deficit/hyperactivity disorder in children and adolescents: Cochrane systematic review with meta-analyses and trial sequential analyses of randomised clinical trials. BMJ (Clinical research ed.), 351, h5203.

Hyry HI, et al. (2015) Compassionate use of orphan drugs. Orphanet journal of rare diseases, 10, 100.

Hsu TR, et al. (2014) Endomyocardial biopsies in patients with left ventricular hypertrophy and a common Chinese later-onset Fabry mutation (IVS4 + 919G > A). Orphanet journal of rare diseases, 9, 96.